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ABSTRACT
Obtaining random homozygous mutants in mam-
malian cells for forward genetic studies has always
been problematic due to the diploid genome. With
one mutation per cell, only one allele of an autosomal
gene can be disrupted, and the resulting heterozy-
gous mutant is unlikely to display a phenotype. In
cells with a genetic background deficient for the
Bloom’s syndrome helicase, such heterozygous
mutants segregate homozygous daughter cells at a
low frequency due to an elevated rate of crossover
following mitotic recombination between homolo-
gous chromosomes. We constructed DNA vectors
that are selectable based on their copy number and
used these to isolate these rare homozygous mutant
cells independent of their phenotype. We use the
piggyBac transposon to limit the initial mutagenesis
to one copy per cell, and select for cells that have
increased the transposon copy number to two or
more. This yields homozygous mutants with two
allelic mutations, but also cells that have duplicated
the mutant chromosome and become aneuploid
during culture. On average, 26% of the copy
number gain events occur by the mitotic recombin-
ation pathway. We obtained homozygous cells
from 40% of the heterozygous mutants tested. This
method can provide homozygous mammalian loss-
of-functionmutantsforforwardgeneticapplications.
INTRODUCTION
Mammalian cell lines provide a convenient model for
mammalian cell biology, particularly in high-throughput
applications where using mice is not feasible. Forward
genetic screens using various cell lines have identiﬁed
genes required for many cellular processes (1).
Gain-of-function screens, where genes are overexpressed
or ectopically expressed, have been successful for many
phenotypes (2,3). However, loss-of-function screens
using mutant cells that lack expression of a particular
gene are harder to conduct in diploid mammalian cells,
as in most cases both alleles of a gene must be knocked out
to see a phenotype. This difﬁculty has meant that
loss-of-function screens have not been applied as widely
as in yeast, Drosophila or Caenorhabditis elegans, where
homozygous mutants can easily be obtained on a
genome-wide scale (4,5).
This problem of obtaining functional null mutants can
be solved using a number of technologies, each with limi-
tations. First, a cell line that is functionally hemizygous
can be used. Chinese hamster ovary cells are one such cell
type in which many loci are functionally hemizygous and
these cells have been used to isolate, for example, X-ray
sensitive mutants, with a single random hit (6). However,
the extent of hemizygosity in the genome of these cells is
unknown and it is likely that not all genes are accessible.
A near-haploid human leukemia cell line has also been
described, which can be used to isolate loss-of-function
mutants in the haploid portion of the genome with a
single hit (7,8). Further derivatives of this cell line (9),
and the recent report of a haploid ES cell line (10), show
promise for screens in the future.
RNA interference (RNAi) screens have also been
used in mammalian cells (11). These act at the mRNA
level and thus the zygosity of the gene is irrelevant.
Many RNAi screens have been performed in mammalian
cell lines, and the reagents are applicable to a variety
of cell types enabling many phenotypes to be studied.
Common problems encountered are incomplete
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where transcripts other than the one predicted are
affected, which can lead to variable results (12,13).
The most robust way to make loss-of-function muta-
tions in a relatively normal cell line would be serially
target both alleles in mouse embryonic stem (ES) cells.
Although resources of targeting vectors and targeted
heterozygous mutant ES cells are increasing in size
[www.knockoutmouse.org and ref. (14)], this is still a
very time-consuming task on the scale required for
genome-wide genetic screens of homozygous mutations.
We have previously used ES cells deﬁcient for the
Bloom syndrome gene [Blm, ref. (15)] to obtain homozy-
gous mutants. Blm-deﬁcient cells (referred to here as
Blm cells for simplicity) have an increased frequency of
crossing over following mitotic recombination relative to
wild-type cells (Figure 1A). In practice, this means that
cells carrying a heterozygous mutation segregate homozy-
gous mutations at division at a low rate of the order
of 10
 4 events/locus/cell/division.
Screens of mutant libraries made in Blm cells have been
successful for phenotypes where null mutants are select-
able, for example resistance to 6-thioguanine (mismatch
repair mutants), aerolysin (glycosylphosphatidylinositol
anchor synthesis mutants) or retroviral infection (16–18).
Reporter systems can also be used to make the phenotype
artiﬁcially selectable (19,20). The requirement for a select-
able phenotype is due to the fact that each potentially
interesting homozygous cell in the library is outnumbered
by the order of one thousand cells heterozygous for the
insertion, which are unlikely to display a loss-of-function
phenotype. We were therefore interested in extending this
method to other non-selectable phenotypes by increasing
the proportion of homozygous cells in the library.
We present here a method to isolate homozygous cells
from these libraries independent of their phenotype.
We use the piggyBac (PB) transposon (21) to cause
loss-of-function insertion mutations and also to deliver a
selection construct that carries two drug resistance genes
but can express only one at a time. The expressed gene can
be switched using Cre recombinase, and only cells with
two copies of this construct can acquire resistance to
both corresponding drugs simultaneously. This allows
selection for the increase in copy number of the
mutation that occurs after loss of heterozygosity (LOH),
and thus for homozygous mutants. We have isolated
homozygous mutants in 48 genes using this method,
which should be applicable on a larger scale to generate
clonal libraries of ES cells with null mutations for genetic
screens.
MATERIALS AND METHODS
Construction of the gene trap vectors
The PB transposon vector, which contains 313bp of the
50 inverted terminal DNA repeat (TR) and 235bp of the
30 inverted TR, has been described previously (19). For the
deletion homozygosity selection vector (DHSV), the PB 50
Figure 1. Copy number selection for recovery of homozygous mutants. (A) Mechanism of LOH in Blm-deﬁcient cells. Blue and red chromosomes
represent homologs. Crossing over between homologous chromosomes is normally suppressed in mitosis (top). In the absence of Blm, crossovers can
occur in G2 phase, forming recombinant chromatids. If these segregate to different daughter cells, LOH occurs distal to the point of crossover. If the
cells carry a heterozygous mutation (represented by the star), this becomes homozygous after LOH, and the copy number of the mutation increases
from one in the starting cell to two in the homozygous daughter. (B and C) Design of vectors for copy number-based selection. The vectors
DHSV (B) and TNN (C) are shown integrated into an intron, with grey boxes representing exons of the disrupted gene; note that TNN can trap
genes transcribed in either direction. SA, splice acceptor; PB5 and PB3, PB repeats.
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ampliﬁed and cloned upstream and downstream of the
selection cassettes. The SA- geo-bpA gene trap cassette
was derived from RGTV1 (18). The Bsd-bpA fragment
was derived from pYTC77 (22). The PGK-loxP-Bsd-
bpA-loxP-PuroDtk-bpA fragment was derived from
pYTC86 (22).
The TNN vector was assembled using a neo gene and
SV40 polyA from pcDNA3 (Invitrogen), and puDTK-bpA
from pYTC86. The mutagens are pairs of terminal exons
with their preceding introns from the genes Ccdc107
and Dom3z, and were ampliﬁed by PCR and cloned in
opposite orientations. These exon pairs were chosen for
small size, constitutive splicing, lack of protein domains
and potential to cause frameshift and premature termin-
ation. The QuikChange site-directed mutagenesis kit
(Stratagene) was used to introduce premature stop
codons in the native reading frame. This is predicted to
cause non-sense-mediated decay of any fusion transcripts
produced, thus increasing the chance that insertions
toward the 30-end of genes, which may not disrupt func-
tional domains, will be mutagenic. The ﬁnal vectors were
conﬁrmed by sequencing and full sequence of these vectors
is available from GenBank under accession numbers
HQ683721 (DHSV1) and HQ683722 (TNN).
ES cell culture and generation of gene trap mutations
Blm-deﬁcient (m3/m4) ES cells (NN5), originally derived
from the AB2.2 ES cell line, were cultured on a layer of
g-irradiated SNL76/7 feeder cells as described previously
(18). Five million cells expanded from a single-cell clone of
NN5 were co-electroporated with 0.5 or 1mg of each gene
trap vector and 10mg of a PBase expression plasmid
(pCAG-PBase). After electroporation, the cells were
cultured on 90mm feeder plates for 3 days without selec-
tion, then trypsinized and replated onto new feeder plates
to reduce mosaicism in individual clones, before applying
G418 selection (180mg/ml, Invitrogen).
Transient expression of Cre plasmid and Cre protein
transduction
Cre was introduced into ES cells by various methods such
as electroporation, lipofection and transduction with
cell-permeable Cre protein (23,24). For electroporation,
20mg of pCAGGS-Cre plasmid was electroporated into
1.0 10
7 ES cells, one-tenth of the electroporated cells
were plated on one 90mm feeder cell plate. Puromycin
(3mg/l, Sigma) and blasticidin S (10mg/l, Invitrogen)
selection was initiated 48h later and continued for
7 days until individual ES cell clones were visible. For
Lipofection, 1mg of pCAGGS-Cre plasmid and 3ml
Lipofectamine 2000 (Invitrogen) were applied to ES cells
cultured in one well of 24-well feeder plate (50% conﬂu-
ent) in accordance with instructions from the manufac-
turer. Two days later, the cells were replated on six-well
plates and drug selection was conducted as above.
Cre transduction was performed as described (23,24). In
brief, one well of 50% conﬂuent ES cells from a 24-well
feeder plate were cultured in 200ml ES cell medium
(without serum and antibiotics) containing 1mM HTNC
(His6-Tat-NLS-Cre) protein produced as previously
described (24) for 8h. After treatment, 1.5ml fresh ES
cell medium (without antibiotics) was added to each
well. Forty-eight hours later, cells were replated on a
six-well plate and drug selection was applied.
For some experiments, an inducible Cre-ERT2 protein
stably expressed from the Rosa26 locus was used. The
Rosa26 locus was targeted as previously described (25)
using a vector provided by Adams,D. and Jonkers,J.
(unpublished data). To induce recombination, cells were
treated with 1mM 4-hydroxytamoxifen overnight.
Splinkerette-PCR to identify transposon insertion sites
Isolation of the transposon–chromosome junction was
performed using the Splinkerette-PCR method as
described (26). Brieﬂy, genomic DNA was isolated from
ES cell colonies on 96- or 24-well plates. Two to three
micrograms of DNA was digested with Sau3AI and
ligated with the corresponding Splinkerette adaptors
HMSp-Sau3AI (generated by annealing Splinkerette
oligos HMSpBb-Sau3AI with HMSpAa). A ﬁrst-round
of PCR was carried out with Splinkerette primer
HMSp1 and PB transposon primers PB50-1 or PB30-1.
Then 1% volume of the PCR product was directly used
for second-round nested PCR that was carried out with
Splinkerette primer HMSp2 and the PB transposon
primers PB50-2 or PB30-2. The nested PCR products
were puriﬁed by High Pure 96 UF cleanup Plate
(Roche) and were used for sequencing with the primer
PB50-seq or PB30-seq separately. All nucleotide positions
are from National Center for Biotechnology Information
(NCBI) mouse build 37.
Genomic PCR and reverse transcription PCR
All primers for genomic PCR and reverse transcription–
PCR (RT–PCR) are described in Supplementary
Table S1.
Karyotyping and Fluorescence in situ hybridisation of
metaphase chromosome spreads of ES cells
Metaphase chromosome spreads were prepared from the
ES cells cultured on 6-well gelatin-treated plates according
to a standard protocol (27). Hybridization was performed
by using appropriate labeled mouse whole chromosome
paints or a speciﬁc DHSV vector probe (27,28).
Adriamycin treatment
Atm
+/+ (NN5), Atm
+/  and Atm
 /  ES cells were plated
on g-irradiated SNL76/7 feeder layer in a series of six-well
plates at a density of 600–800 cells/well. Twenty-four
hours later, cells were treated with graded concentration
of adriamycin (Sigma) for 7h and then replaced with fresh
ES cell medium. The surviving ES cell colonies in each
well were counted after 7–9 days of culture.
PAGE 3 OF 10 Nucleic AcidsResearch, 2012, Vol.40,No. 3 e21RESULTS
Copy number-based selection vectors
We considered that the copy number of the mutagenesis
vector could be used to discriminate homozygous and
heterozygous cells, and thus to select for homozygous
mutants independently of phenotype. If the initial
mutagenesis is limited to one mutation per cell, then
homozygous mutant cells will have two mutations (at
allelic positions). We therefore designed reporter
constructs that are selectable based on the number of
expressed copies in the cell. These constructs contain
only one promoter and coding sequence for two different
resistance genes. The two genes are expressed mutually
exclusively; the expressed gene can be switched by the
action of Cre recombinase. This is achieved either by
deletion of one of the genes (vector DHSV, Figure 1B)
or inversion when the genes are arranged tail-to-tail
(vector TNN; Figure 1C). DHSV contains tandemly
arranged bsd and puroDTK genes (29) that confer
blasticidin and puromycin resistance, respectively. TNN
contains puroDTK and a neo gene, which confers resist-
ance to the drug G418, in the opposite orientation.
Cells bearing a single copy of such a construct can only
be resistant to one drug at a time. However, in the case
where cells have two or more copies of the construct, tran-
sient treatment with Cre will result in some cells with both
forms of the construct, expressing both resistance genes.
These cells will be resistant to both drugs. Thus, these
constructs are predicted to allow stringent selection
against cells with only one copy (i.e. heterozygous
mutants) and to recover a subset of cells with two or
more copies (homozygous mutants).
Steps to increase the number of mutable loci
As well as the copy number selection cassette, each vector
contains mutagenic elements designed to disrupt splicing.
The constructs are ﬂanked by TR sequences of the PB
transposon for efﬁcient delivery into the genome of
mammalian cells. PB is highly active in ES cells and
exhibits wide genome coverage (30,31). Moreover,
 50% of PB insertions occur in genes, making it an
ideal mutagenesis vector (32). The DHSV vector
contains a conventional selectable gene trap based on
the ß-geo gene, which combines G418 resistance with a
lacZ reporter (33). Selectable gene trap vectors ensure
that each insertion is in a gene, although there is a require-
ment for this gene to be expressed at the time of mutagen-
esis. PB appears to have wider genome coverage than
the retroviruses used for gene trap mutagenesis—a
previous study isolating components of the mismatch
repair pathway showed that PB mutagenesis found more
known components of the pathway than retroviral
mutagenesis (34). As an option to further increase
coverage, the TNN vector includes two non-selectable
gene trap cassettes. These consist of pairs of exons and
splice acceptors, containing multiple premature stop
codons in all reading frames that are predicted to cause
non-sense-mediated decay of fusion transcripts (35). These
were designed to maximize the chance of causing a
mutation, given that PB insertions frequently occur in
genes, without requiring sustained expression of the
gene trap coding sequence.
Homozygous mutants recovered using selection for copy
number increase
We applied these constructs to the selection of rare homo-
zygous mutants that arise in cultures of heterozygously
mutated Blm-deﬁcient cells. Using transfection conditions
in which a PB transposase expression plasmid is
cotransfected with a limiting amount of transposon
donor plasmid, we obtained hundreds of clonal Blm-deﬁ-
cient mouse ES cell lines. The majority of these contain a
single-copy integration of the transposon (Figure 2A).
Selection with both drugs at this point did not yield any
double-resistant subclones (data not shown). For each cell
line, we mapped the transposon integration site by
Splinkerette-PCR. After culturing these cell lines for
several passages, we could isolate double drug-resistant
subclones after providing Cre by transfection of an expres-
sion plasmid, transduction with cell-permeable Cre
protein or activation of an inducible ERT2-Cre transgene
(Figure 2B). Some cell lines produced very large numbers
of double-resistant subclones, comparable to the number
of cells plated; these lines contained two or more
non-allelic transposon insertions (Figure 2C, well 5) and
were not analyzed further. Some lines did not yield
double-resistant cells. However, for most lines we
obtained varying numbers of double-resistant subclones,
of the order of one per 10
2–10
4 cells plated (Figure 2C).
We genotyped these double-resistant subclones to deter-
mine whether these represented homozygous mutants.
We assessed presence of the wild-type and mutant alleles
by PCR using primers designed to ﬂank the transposon
integration site, along with a common primer that hybrid-
izes to one transposon terminus and extends outwards
(Figure 2D). For some cell lines, all double-resistant
subclones showed the expected result for a homozygous
mutant—ampliﬁcation of only the PCR product from
the mutant allele, and loss of the wild-type allele
(Figure 2E). However, for most cell lines we observed
some double-resistant subclones from which a wild-type
PCR product could be ampliﬁed (Figure 2F), and in some
cases all double-resistant subclones retained a wild-type
locus as assessed in this PCR assay (Figure 2G).
Double-resistant clones that retain a wild-type locus
are aneuploid
Further investigation of these subclones that retained the
wild-type locus by Southern blot revealed that although
there were two allelic copies of the transposon present,
these were accompanied by one or more extra wild-type
chromosomes. In some cases, the cells had a tetraploid
karyotype (Figure 3A–D), while in others only the
chromosome with the insertion site was in excess
(Figure 3E). These data show that LOH is not the only
pathway for copy number increase in Blm-deﬁcient cells,
and that acquisition of aneuploidy is the major alternative
pathway. Across all cell lines that we investigated, the
average proportion of genuine homozygous mutant
e21 Nucleic Acids Research, 2012,Vol. 40,No. 3 PAGE 4 OF 10subclones isolated was 26% (Table 1). As the rate of LOH
is low even in Blm-deﬁcient ES cells (4.2 10
 4 events/
locus/cell/division), this represents a 25- to 250-fold en-
richment for homozygous mutants, which would be
expected to form only 0.1–1% of the culture prior to
double selection
LOH rate at different loci
As the process of LOH depends on a recombination event
between the locus in question and the centromere, it is
possible that it would be difﬁcult to obtain homozygous
mutants for loci close to the centromere. To address this,
we measured the rate of LOH at three different loci on
chromosome 11, one of which was a targeted insertion
of a PGK-puroDTK cassette at the Gdf9 locus, where
previous measurements of the LOH rate in Blm-deﬁcient
ES cells have been made (15). We isolated other chromo-
some 11 insertions of TNN in the puro orientation
(Figure 4A). In all of these cases, the wild-type cell that
results from crossover and loss of the puroDTK cassette
can be isolated by selection in 1-(2-deoxy-2-ﬂuoro-1-d-
arabinofuranosyl)-5-iodouracil; 200nM (FIAU). For
each locus we set up replicate cultures starting from a
single cell, allowed them to expand to 7.5 10
5 cells and
selected cells with LOH events in FIAU (Figure 4B). The
rate of LOH was calculated by the ﬂuctuation analysis
using the method of medians (36), and did show an
increase with distance from the centromere (Table 2).
The rates were lower than previously measured using
HPRT for negative selection, even for Gdf9 (previously
measured as 4.2 10
 4). This may be related to the use
of DTK for selection in this case. We found that the LOH
rate varied by a factor of four over the 20–96 Mb range
tested. As 92% of genes lie >20 Mb from the centromere
[Figure 4C, ref. (37)], the probability of crossover is not
likely to limit the recovery of homozygous mutants for the
vast majority of loci.
The mutagenesis vectors cause null mutations
Homozygotes were readily isolated using both the deletion
(DHSV) and inversion (TNN) vectors. For one insertion
of DHSV in the Atm gene (Figure 5A), which encodes the
ataxia telangiectasia-mutated kinase involved in the DNA
damage response (38,39), we obtained three homozygous
Figure 2. Isolation of homozygous mutants by selection for copy number increase. (A) Transposition using limiting amounts of transposon donor
plasmid results in most G418 resistant subclones having one transposon per cell. (B) Selection scheme, showing predicted number and type of
transposon present at each stage. (C) Typical result of double-selection stage. Well 5 has two non-allelic transposon integrations to begin with and
thus all cells can become double resistant. (D) Genotyping scheme—primer positions (1–3) are shown relative to the transposon integration site.
(E) All double-resistant subclones (derived from an integration in Dhx35) fail to amplify the wild-type PCR product. (F and G) Examples of
double-resistant populations in which some (F) and all (G) subclones have a wild-type allele.
PAGE 5 OF 10 Nucleic AcidsResearch, 2012, Vol.40,No. 3 e21subclones after double selection (Figure 5B). Although,
the vector was oriented with the splice acceptor in the
opposing direction, and is therefore trapping another
promoter in this instance, Atm transcription was effective-
ly disrupted (Figure 5C). Mutant subclones showed sensi-
tivity to the DNA damaging drug adriamycin, as expected
for an Atm null mutant. In all other cases that we tested,
both the DHSV and TNN vectors effectively disrupted
transcription of genes that they were inserted into as
assessed by RT–PCR (Figure 6). These data show that
mutations generated with DHSV or TNN cause null
mutations and therefore can be used to screen non-
selectable phenotypes.
DISCUSSION
We have developed a method for enriching libraries of
Blm-deﬁcient ES cells carrying single-copy transposon
mutations for homozygous mutants. The method is
based on selection for two copies of the transposon con-
struct in the rare homozygous mutants, which is achieved
by a switchable drug selection cassette. Using our method
of single-copy mutagenesis, clonal expansion, cassette
switching by Cre recombinase and selection for two
copies, we obtained double-drug resistant populations
enriched in homozygous mutants. The proportion of
homozygous mutants increased from a predicted 0.1%
in the expanded unselected population to a measured
Figure 3. Abnormal karyotype of clones that retain a wild-type allele. (A) Structure of Myo10 locus analyzed in (B–D). (B) PCR genotyping as in
Figure 2D. All double-resistant subclones retain the wild-type allele. (C) All these subclones have a single-transposon integration site (top) but
contain both pre- (In: insertion) and post-Cre (Del: deleted) forms of the transposon (bottom). (D) Spectral karyotype showing tetraploidy in
a double-resistant subclone. (E) An example of a less severe aberration—only chromosome 6, which bears the insertion at the Grid2 locus, is present
in excess. Left, FISH showing three copies of chromosome 6 with (white arrows) and without (yellow arrow) transposon insertions (red dots).
Right, spectral karyotype.
Table 1. Number and proportion of homozygous mutant clones isolated using each vector
Vector Clones analyzed Clones with homozygotes Clones with homozygotes (%) Mean hom:het ratio in subclones (%)
a
DHSV 89 36 40 23
TNN 19 12 63 34
Combined 108 48 44 26
aIncludes clones for which no homozygous subclones were isolated.
e21 Nucleic Acids Research, 2012,Vol. 40,No. 3 PAGE 6 OF 10Figure 5. Insertion of DHSV at Atm causes DNA damage sensitivity. (A) Structure of mutant Atm locus. (B) Triple primer PCR genotyping using
primers a, b and c shown in (A). Clones 2, 3 and 5 lack the wild-type band, consistent with being homozygous mutants. (C) RT–PCR showing loss of
Atm transcript. Internal primers to LacZ were included as a positive control. (D) Atm mutants are hypersensitive to adriamycin. Mean surviving
fraction (colonies) is plotted. NN5, n=2; Atm
 / , n=3. Error bars show SEM.
Figure 4. Measurement of LOH rate at different loci. (A) Position of loci investigated on chromosome 11. (B) Number of FIAU resistant colonies
obtained (one-tenth of each culture was plated). Data are shown in the original random order, and the rate calculation shown in Table 2.
(C) Cumulative frequency plot of all Vega-curated gene start sites (37). The positions of the loci investigated here are marked.
Table 2. Calculation of the rate of LOH at three loci on chromosome 11 by ﬂuctuation analysis
Locus Mb Cultures Median
FIAU
R/culture
Plating
efﬁciency
Mean
cells/culture
LOH events/culture
(mh)
a
LOH rate
(10
 5 events/cell/division)
D8 21 19 1 0.35 753000 7.53 0.99
Gdf9 54 14 3.5 0.38 762000 18.56 2.5
F8 96 18 6.5 0.27 739000 40.95 5.5
aSee ref. (34) for details of calculation. FIAU
R, FIAU-resistant colonies.
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double-resistant population. This increased proportion
means that homozygous mutants can be obtained by
picking relatively small numbers of subclones. It is
possible that this number is an underestimate where
clones were genotyped by absence of wild-type locus by
PCR, as this may be very sensitive to contamination either
between clones or from wild-type feeder cells.
Genotyping of subclones from the double-drug resistant
populations revealed two classes of mutants. We found
that while some subclones had lost the wild-type locus,
consistent with a homozygous mutant, others retained a
wild-type locus that could be ampliﬁed by PCR. Further
analysis of some of these clones revealed numerical
chromosome abnormalities, either genome wide (tetra-
ploidy) or affecting the chromosome bearing the trans-
poson insertion (trisomy). We conclude that our method
faithfully selects for two copies of the construct, and there
are two routes by which Blm cells can increase mutation
copy number—the predicted LOH pathway and by
numerical chromosome instability (Figure 7). Often we
isolated similar numbers of these two classes of double-
resistant subclone, suggesting that each of these events
occurs at a similar low rate. In some cases, this may be
exacerbated by a growth advantage linked to trisomy,
particularly for chromosomes 8, 11 and 16 (40–42).
Figure 6. Robust disruption of transcription in homozygous mutants. (A) PCR genotyping of DHSV insertion in Ddef2 using primers for mutant
(Junction, left) and wild-type alleles. All double-resistant subclones are homozygous mutants. (B) RT–PCR showing ampliﬁcation of fusion transcript
(left) and loss of wild-type transcript (right) in double-resistant subclones. (C and D) Insertions of the TNN vector also disrupt transcription. PCR
and RT–PCR genotyping is shown for insertions in Dym (C) and Arrb2 (D). Asterisks indicate homozygous mutant subclones, all of which have lost
wild-type transcript expression. Minus indicates no template control, Actb is an internal control.
Figure 7. Pathways for copy number gain in Blm-deﬁcient cells.
Most cell divisions do not result in copy number increase (left). The
two pathways of mitotic recombination (middle) and aneuploidy acqui-
sition (right) result in copy number gain and contribute to the
double-resistant population.
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from insertions on these chromosomes.
The system of selection for copy number increase in
Blm-deﬁcient ES cells could be applied more broadly to
obtain large collections of mutants for study, for example
in genetic screens. Using the procedure described above,
we isolated homozygous mutants for 48 out of 108 cell
lines tested (Table 1 and Supplementary Tables S1 and
S2). We screened relatively small numbers of subclones
(usually six or fewer); therefore it is possible that
homozygous mutants could be isolated for some of the
remaining 60 cell lines by screening further subclones.
We were unable to isolate homozygous mutants for
some clones, either because no double-resistant cells
were obtained or because all double-resistant subclones
analyzed retained the wild-type locus. This could be
simply because the events leading to double resistance
are rare and may not occur in every expanded clone, or
because only a chromosome instability event and not an
LOH event occurs. Another explanation could be that the
gene mutated is essential for ES cell survival or growth,
and therefore homozygous cells do not survive or are at a
growth disadvantage compared with wild-type retaining
cells. This is likely to be the case for some clones that
we tested, for example Faf1, a mutant of which has been
reported to cause early embryonic lethality and for which
no homozygotes were isolated using our system (43).
It should also be noted that when the DHSV vector is
used, double-resistant cells may not be recovered if Cre
is very efﬁcient and causes deletion in both copies of the
resistant cassette. In the case of TNN, the theoretical
chance of isolating a cell with two copies is 50% if the
Cre reaction reaches an effective equilibrium—this repre-
sents the probability that both copies are in different
orientations. However, we did not notice an overall differ-
ence in the number of double-resistant clones isolated
with each vector in practice.
The Blm mutant alleles used here are constitutive, rather
than inducible, mutations. Since Blm is a key regulator
of homologous recombination (44), there is cause for
concern that a constitutive mutation may result in
ongoing genome instability. We have not observed high
levels of gross chromosomal instability, for example
genuine homozygotes isolated from cell lines that also
gave aneuploid subclones usually have a normal diploid
karyotype (at the microscopic level). An inducible Blm
allele (17) is an obvious potential improvement to the
system, and a similar system has been developed using
such an allele (45). Even in this case, Blm function must
be still disrupted to allow LOH, hence an inducible allele
will not improve genome stability during the homozygote
isolation process, although it would allow for formal sep-
aration of the effects of the transposon-induced mutations
from the Blm-deﬁcient genetic background.
Even better validation of mutations could come from
resources of targeted mouse ES cell knockouts and target-
ing vectors, which are increasing in size to the point where
obtaining a heterozygous mutant in a gene of interest will
become trivial. These ES cell lines can be used to generate
homozygous mutants after disruption of the remaining
wild-type allele using the vectors provided (14,46). Given
the ease of obtaining mutants from the public resources in
a low-passage cell line with a ‘clean’ genetic background,
this represents the best option for further functional
study. Mammalian screening methods such as the one
we describe here are an excellent complement to these
resources, as they provide rapid functional information
to prioritize study of the available mutants.
In conclusion, we describe a system using PB trans-
poson constructs that cause null mutations with wide
genome coverage in mouse ES cells that are a versatile
model mammalian cell type. The mutations generated
are stable, but reversion can be induced and selected for
by a second round of transposition to allow phenotype
rescue experiments (26). This gives a robust link between
genotype and phenotype, representing a key advantage
compared to RNAi-based screens where causally linking
the phenotype to the targeted gene can be problematic.
Moreover, other mutations or reporter constructs can
easily be introduced into the Blm-deﬁcient cells to create
customized libraries for more sophisticated screens. By
providing easy access to elusive homozygous mammalian
mutant cells, our method signiﬁcantly expands the scope
of genetic screens and future functional studies in mam-
malian cells.
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